|
Cours en clôture
Shenzhen S.E.
27/07/2026
|
Varia. 5j.
|
Varia. 1 janv.
|
|
4,460 CNY
|
+1,13%
|
 |
-0,89%
|
+2,53%
|
|
22/06 |
Guizhou Bailing's Three Products Chosen for China's Centralized Procurement for Traditional Medicine
| | |
19/05 |
Guizhou Bailing Group Pharmaceutical Gets Seven-Year Protection Status for Traditional Chinese Drug Spray
| | |
27/04 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
| | |
27/04 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
| | |
30/12 |
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from S&P Global BMI Index
| | |
19/12 |
Guizhou Bailing's trading to halt to implement other risk warning
| | |
03/12 |
Guizhou Bailing Group Pharmaceutical's actual controller investigated for suspected rule violations
| | |
24/10/25 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
| | |
16/10/25 |
Guizhou Bailing's Unit Gets Nod to Trial Tangning Tongluo Tablets
| | |
22/09/25 |
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) added to S&P Global BMI Index
| | |
19/08/25 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
| | |
29/04/25 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
| | |
28/04/25 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
| | |
13/11/24 |
Bailing Pharma Gets Clinical Trial Approval for Diabetic Retinopathy Traditional Chinese Tablets; Shares Rise 5%
| | |
25/10/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
| | |
27/08/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
| | |
02/08/24 |
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.
| | |
02/08/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 3, 2024 has closed with 20,491,812 shares, representing 1.48% for CNY 119.59 million.
| | |
01/07/24 |
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.
| | |
21/05/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from FTSE All-World Index
| | |
10/05/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from S&P Global BMI Index
| | |
03/05/24 |
Large-Scale Equipment Renewals Seen to Raise Demand for Chinese High-End Steel Products, Trade Body Says
| | |
02/05/24 |
China to Tweak Production Limits for Steel as Industry Faces Low Prices, Oversupply
| | |
29/04/24 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
| | |
02/04/24 |
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.
| |
Aucun résultat pour cette recherche Sélectionnez votre édition Toutes les informations financières adaptées au niveau national | 
